“…Furthermore, the good biocompatibility and bioavailability, lower release kinetics, and capability of enclosing drugs have made liposomes the most common type of FDA-approved nanomaterial for drug or gene delivery nanosystems to treat ocular diseases. 123,124 However, liposome nanoparticles are also limited by low drug load and low biological distribution. After decades of development, liposomes have been widely used in various fields, including the delivery of drugs, genes, vaccines, and imaging agents.…”